Introduction
SCLC, cancers, cancer, malignant tumors, toxic alkylating, tumors
CANCERS, SCLC, CANCER, SOLID TUMORS, MALIGNANT TUMORS, SMALL CELL LUNG CANCER, TUMORS, METASTATIC BREAST CANCER
Drug therapies for malignant tumors include chemotherapy, hormone therapy, and molecular-targeted therapy, and a combination of these therapies has been used in clinical settings. Chemotherapy has long been used to treat cancer and remains the backbone of systemic treatment in most cancers. Bendamustine hydrochloride (bendamustine) is a less toxic alkylating agent composed of three structures: a nitrogen mustard skeleton, benzimidazole ring, and butyric acid side chain. It was first synthesized in the German Democratic Republic in 1963 [The alkylation activity of bendamustine was found to be more potent than that of other alkylating agents in previous studies [Bendamustine has also been extensively evaluated for the treatment of solid tumors, and its activity has been observed in patients with metastatic breast cancer (mBC) and small cell lung cancer (SCLC) [Oral administration of bendamustine to humans was first reported by Preiss et al. in 1985, and a moderate bioavailability of 57% was reported [The development of a new oral dosing schedule for orally-administered bendamustine that ensures a balance between efficacy and safety will provide a new treatment option for patients with advanced solid tumors. In this study, we employed a standard 3 + 3 dose escalation design to evaluate the safety and pharmacokinetics (PK) and to determine the recommended dose (RD) and optimal dosing schedule of orally-administered bendamustine in patients with advanced solid tumors. Furthermore, we explored the types of tumors that were sensitive to orally-administered bendamustine.